Compare Amgen, Inc. (AMGN) vs Royal Bank of Canada (RY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Royal Bank of Canada — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Royal Bank of Canada trades at $208.97 (market cap $292.49B). The key difference: Royal Bank of Canada is the larger of the two by market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | RY | |
|---|---|---|
Market Cap | $196.12B | $292.49B |
Sector | Health | Financials |
52-Week High | $388.16 | $211.09 |
52-Week Low | $271.18 | $128.46 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | 2.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Royal Bank of Canada (RY) trades at $211.09, up 1.21% today, with a bullish technical signal and strong fundamental performance. Recent quarterly earnings consistently beat estimates, with Q1 2026 EPS of $2.84 exceeding the $2.81 forecast. Revenue grew to $66.53B in 2025, and net income margin improved to 31.85%. The company maintains a solid dividend, recently increasing it to $1.76 per share, and announced a share repurchase program.
RY's outlook is positive, supported by earnings momentum and shareholder returns, but faces risks from economic softness and high valuation multiples. Analyst sentiment is mixed, with a majority hold rating, reflecting caution amid rich valuations. The stock's current price near resistance at $211 suggests potential for consolidation before further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Royal Bank of Canada
Royal Bank of Canada is one of the two largest banks in Canada. It is a diversified financial services company, offering personal and commercial banking, wealth-management services, insurance, corporate banking, and capital markets services. The bank is concentrated in Canada, with additional operations in the U.S. and other countries.
Read more on RY →
